MX2021000908A - Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. - Google Patents

Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Info

Publication number
MX2021000908A
MX2021000908A MX2021000908A MX2021000908A MX2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A
Authority
MX
Mexico
Prior art keywords
breathlessness
dyspnea
treatment
chronic cough
cough
Prior art date
Application number
MX2021000908A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2021000908A publication Critical patent/MX2021000908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2021000908A 2018-07-23 2019-07-23 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. MX2021000908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701902P 2018-07-23 2018-07-23
PCT/US2019/042994 WO2020023486A1 (en) 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea

Publications (1)

Publication Number Publication Date
MX2021000908A true MX2021000908A (es) 2021-06-08

Family

ID=69162461

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000908A MX2021000908A (es) 2018-07-23 2019-07-23 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2024009649A MX2024009649A (es) 2018-07-23 2021-01-22 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009649A MX2024009649A (es) 2018-07-23 2021-01-22 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Country Status (12)

Country Link
US (5) US20200022974A1 (https=)
EP (1) EP3826635A4 (https=)
JP (2) JP2021531299A (https=)
KR (1) KR20210035854A (https=)
CN (5) CN112703000B (https=)
AU (2) AU2019309913B2 (https=)
BR (2) BR112021001177A2 (https=)
CA (1) CA3106995A1 (https=)
IL (2) IL318587A (https=)
MX (2) MX2021000908A (https=)
SG (1) SG11202100580UA (https=)
WO (1) WO2020023486A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
KR20220127849A (ko) * 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
WO2026025110A1 (en) * 2024-07-26 2026-01-29 Trevi Therapeutics, Inc. Treatment of refractory chronic cough

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443442A (en) 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
AU8952282A (en) 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
ES2236630T3 (es) 1996-11-25 2005-07-16 Toray Industries, Inc. Agente antipruritico.
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
MXPA99011298A (es) 1997-07-14 2004-10-28 Adolor Corp Formulaciones farmaceuticas antiprurito de agonista kappa y metodo para tratar prurito con las mismas.
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
JP4370683B2 (ja) 2000-05-08 2009-11-25 東レ株式会社 そう痒疾患の検査方法
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
ITMI20010907A1 (it) 2001-05-02 2002-11-02 Valpharma Sa Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
US20030054030A1 (en) 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
ES2654819T3 (es) 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
SI2263691T1 (sl) 2002-07-15 2012-12-31 F. Hoffmann-La Roche Ag Zdravljenje raka z rekombinantnim humaniziranim monoklonskim anti-ErbB2 protitelesom 2C4 (rhuMAb 2C4)
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
DE602004026604D1 (de) 2003-09-25 2010-05-27 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
JP4882744B2 (ja) 2004-03-30 2012-02-22 東レ株式会社 止痒剤
EP1763349A2 (en) 2004-06-03 2007-03-21 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
ES2462541T3 (es) 2005-06-09 2014-05-23 Meda Ab Método y composición para el tratamiento de trastornos inflamatorios
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
JP2009506080A (ja) 2005-08-30 2009-02-12 クィーンズ ユニバーシティー アット キングストン 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
JP2008109898A (ja) 2006-10-31 2008-05-15 Toray Ind Inc 鎮痒作用を有する化合物のスクリーニング方法
MX2009005000A (es) 2006-11-10 2009-10-12 Cara Therapeutics Inc Amidas de peptidos sinteticos.
AU2007352557A1 (en) 2006-11-22 2008-11-13 Progenics Pharmaceuticals, Inc. (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
US20080176884A1 (en) 2006-11-22 2008-07-24 Progenics Pharmaceuticals, Inc. 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs
EP2099456A2 (en) 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
WO2008129000A1 (en) 2007-04-20 2008-10-30 Novartis Ag Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
ES2396600T3 (es) 2007-04-23 2013-02-22 Symrise Ag Ésteres de polietilenglicol y preparaciones cosméticas y/o dermatológicas
WO2009000878A1 (en) 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
EP2197427A2 (en) 2007-09-04 2010-06-23 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
US20090093509A1 (en) 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
US20110112129A2 (en) 2007-11-26 2011-05-12 Pharmacofore, Inc. Peripheral Phenolic Opioid Antagonist
WO2009103004A1 (en) 2008-02-14 2009-08-20 Alkermes, Inc. Selective opioid compounds
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
WO2009132313A2 (en) 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
US20110262446A1 (en) * 2008-10-14 2011-10-27 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
EA201101207A1 (ru) 2009-02-24 2012-04-30 Новартис Аг Применение антагонистов рецептора nk
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
EP3170395A1 (en) 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
AU2010238925A1 (en) 2009-04-22 2011-12-15 Phoeme Gmbh Particulate pharmaceutical composition having an opioid and an opioid antagonist
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US9364623B2 (en) * 2009-07-15 2016-06-14 UNIVERSITé LAVAL Method and device for administering oxygen to a patient and monitoring the patient
AU2011211223B2 (en) 2010-01-29 2014-10-23 Toray Industries, Inc. Therapeutic or prophylactic agent for biliary diseases
IT1398930B1 (it) 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
ES2984559T3 (es) 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
RU2650118C2 (ru) * 2013-08-23 2018-04-09 Афферент Фармасьютикалз Инк. Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
MX2016016404A (es) 2014-06-13 2017-11-30 Trevi Therapeutics Inc Metodos para el tratamiento del prurito.
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
CA3008920C (en) * 2015-12-23 2024-09-17 Conrig Pharma Aps SUPLATAST TOSILATE FOR THE TREATMENT OF COUGH ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
WO2017120468A1 (en) 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
RS59313B1 (sr) * 2016-01-08 2019-10-31 Nerre Therapeutics Ltd Orvepitant za lečenje hroničnog kašlja
CN105560202B (zh) 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CN109310656A (zh) 2016-03-21 2019-02-05 特雷维治疗股份有限公司 尿毒症性瘙痒症的治疗
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
MX2019004804A (es) 2016-10-25 2019-08-22 Trevi Therapeutics Inc Tratamiento para el prurigo nodula.
AU2019301134A1 (en) 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療

Also Published As

Publication number Publication date
MX2024009649A (es) 2024-08-19
US20250339424A1 (en) 2025-11-06
US20220218697A1 (en) 2022-07-14
CA3106995A1 (en) 2020-01-30
CN118512452A (zh) 2024-08-20
CN118477079A (zh) 2024-08-13
JP2024153828A (ja) 2024-10-29
EP3826635A1 (en) 2021-06-02
BR112021001177A2 (pt) 2021-04-27
BR122023024228A2 (pt) 2024-02-20
JP2021531299A (ja) 2021-11-18
AU2019309913A1 (en) 2021-03-11
SG11202100580UA (en) 2021-02-25
US11660296B2 (en) 2023-05-30
CN118512453A (zh) 2024-08-20
AU2025203754A1 (en) 2025-06-12
WO2020023486A1 (en) 2020-01-30
US20240423975A1 (en) 2024-12-26
IL318587A (en) 2025-03-01
EP3826635A4 (en) 2022-04-27
CN112703000A (zh) 2021-04-23
IL280301B1 (en) 2025-02-01
KR20210035854A (ko) 2021-04-01
IL280301A (en) 2021-03-01
IL280301B2 (en) 2025-06-01
US20220409613A1 (en) 2022-12-29
CN118512451A (zh) 2024-08-20
CN112703000B (zh) 2024-05-31
AU2019309913B2 (en) 2025-02-27
US20200022974A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2023008193A (es) Procedimientos para tratar el cáncer.
MY190034A (en) Method of treating cancer associated with a ras mutation
ZA201804513B (en) Method of treating c3 glomerulopathy
EP4417252A3 (en) Cannabis based therapeutic and method of use
MX2017010150A (es) Bacterias probioticas recombinantes.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2024009649A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
EP3488877A4 (en) IMPLANT AND KIT FOR THE TREATMENT OF BONE DAMAGE, AS WELL AS THE METHOD FOR THE TREATMENT OF BONE DAMAGE.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
IL267958B1 (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
WO2019043649A3 (en) ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
EA202193276A1 (ru) Способы лечения холангиокарциномы
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.